Clinical trials: Symptom
Chronic Lymphocytic Leukemia
Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512)
The primary objective of this extension study (GS-US-312-0117) that is a companion study to Study GS-US-312-0116 (NCT01539512), is to evaluate the effect of idelalisib on the onset, magnitude, and duration of tumor control.
- Trial name
- NCT01539291
- Testing
- Idelalisib
- Where
- 45 sites in United States, France and 3 more
- Volunteers
- 161 people
- Sponsor
- Gilead Sciences
Molluscum Contagiosum
Cantharidin Application in Molluscum Patients-1
This study is a Phase 3, randomized, double-blind, placebo-controlled, pivotal study to evaluate the safety and efficacy of VP-102 topical film-forming solution in subjects with Molluscum Contagiosum.
- Trial name
- CAMP-1 (NCT03377790)
- Testing
- VP-102 - Cantharidin, Topical Film Forming Solution
- Where
- 18 sites in United States
- Volunteers
- 266 people
- Sponsor
- Verrica Pharmaceuticals Inc.
Lymphedema, Lymphedema of Face
A Study Evaluating an Advanced Pneumatic Compression Device Versus Usual Care for Treatment of Head and Neck Lymphedema
To compare the effectiveness of an APCD to Usual Care in the management of lymphedema and fibrosis (LEF) in head and neck cancer (HNC) survivors.
- Conditions
- Lymphedema, Lymphedema of Face, Lymphedema, Secondary, Lymphedema Due to Radiation
- Trial name
- NCT04797390
- Testing
- Advanced Pneumatic Compression Device (APCD), Usual Care
- Where
- 10 sites in United States
- Volunteers
- 236 people
- Sponsor
- Tactile Medical
Ovarian Cancer
A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer
The purpose of this study is to evaluate the effect of BSI-201 on the objective response rate in platinum-sensitive recurrent ovarian cancer patients receiving gemcitabine and carboplatin.
- Trial name
- NCT01033123
- Testing
- BSI-201
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Sanofi
Chronic Migraine, Headache
A Retrospective Study to Evaluate the Effectiveness of onabotulinumtoxinA in Preventing Headaches in Patients With Chronic Migraines
This study will evaluate the effectiveness of OnabotulinumtoxinA to prevent headaches in patients with Chronic Migraine.
- Trial name
- NCT01749423
- Testing
- OnabotulinumtoxinA
- Sponsor
- Allergan
Angina Pectoris
Phase III Trial of Dantonic® (T89) Capsule to Prevent and Treat Stable Angina
This phase III study is designed as a double blind, randomized, multi-nation, multi-center, placebo controlled clinical research, which aims to evaluate the safety and efficacy of Dantonic® (T89) in patients with chronic stable…
- Trial name
- CAESA (NCT01659580)
- Testing
- T89 high dose, T89 Low dose, Sanqi+Bingpian
- Where
- 94 sites in United States, Belarus and 5 more
- Volunteers
- 1,004 people
- Sponsor
- Tasly Pharmaceuticals, Inc.
Liver Cancer (Primary and Metastatic)
Short-term Embolization Using Gelatin Particles for FloW ModulAtion During Y90 Radioembolization
The SEGWAY trial is a prospective, single-arm clinical study to evaluate the efficacy and safety of flow diversion to protect non-tumorous liver function using short-acting gelatin sponge particles during Yttrium-90…
- Trial name
- SEGWAY (NCT06229080)
- Testing
- NexGel
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Next Biomedical Co., Ltd.
Neurogenic Detrusor Overactivity, Overactive Bladder
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder
The purpose of this study is to evaluate the pharmacokinetics as well as the safety and tolerability of mirabegron OCAS tablets after single-dose administration at different dose levels in children and adolescents with NDO or OAB.
- Conditions
- Neurogenic Detrusor Overactivity, Overactive Bladder, Pharmacokinetics of Mirabegron
- Trial name
- NCT02211846
- Testing
- Mirabegron
- Where
- 13 sites in Belgium, Denmark and 3 more
- Volunteers
- 34 people
- Sponsor
- Astellas Pharma Inc
Prostate Cancer
Evaluation of the Sentinel™ PCC4 Assay for Diagnosis, Prognosis and Monitoring of Prostate Cancer in Puerto Rico
The miR Scientific Sentinel™ Prostate Cancer Classifier Platform (Sentinel™ PCC4 Assay) is a new molecular assay that interrogates 442 small non-coding RNAs extracted from urinary exosomes and provides urologists an early, very…
- Trial name
- NCT04661176
- Testing
- miR Sentinel™ PCC4 Assay
- Where
- 3 sites in Puerto Rico
- Volunteers
- 500 people
- Sponsor
- miR Scientific LLC
Mild Cognitive Impairment (MCI), Early Stages of Cognitive Decline
Mild Cognitive Impairment Community Screening and Early Intervention Via Stem Cell Therapy and Wearable Brain Computer Interface Device.
This study aims to evaluate the efficacy of community-based early detection and targeted interventions, including stem cell therapy and wearable non-invasive brain-computer interface (BCI) devices, for Mild Cognitive Impairment…
- Conditions
- Mild Cognitive Impairment (MCI), Early Stages of Cognitive Decline, Alzheimer's Disease Dementia, Alzheimer's Disease Diagnosis
- Trial name
- MCITestCare (NCT07214974)
- Testing
- Structured wellness care, Wearable brain-computer interface devices, Stem Cell Therapy - Experimental
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Noah Tech, Corp.
Bipolar Disorder
Study Evaluating Cariprazine (RGH-188) in the Treatment of Patients With Acute Mania
This is a study designed to evaluate the efficacy, safety, and tolerability of RGH-188 monotherapy in the treatment of acute mania.
- Trial name
- NCT00488618
- Testing
- Cariprazine (RGH-188)
- Where
- United States
- Volunteers
- 238 people
- Sponsor
- Forest Laboratories
Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive
Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis
The purpose of this study is to compare the safety and efficacy of masitinib 6 mg/kg/day versus placebo in the treatment of patients with primary progressive multiple sclerosis or relapse-free secondary progressive multiple…
- Conditions
- Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Relapse Free
- Trial name
- NCT01433497
- Testing
- Masitinib
- Where
- 8 sites in Bulgaria, France and 5 more
- Volunteers
- 656 people
- Sponsor
- AB Science
Myocardial Infarction
Single Bolus Recombinant Nonimmunogenic Staphylokinase Versus Single Bolus Tenecteplase (Metalyse) in STEMI
The aim of the study is to determine if single-bolus recombinant nonimmunogenic staphylokinase is effective and save thrombolytic agent in patients presenting ST-segment elevation myocardial infarction in comparison to…
- Trial name
- FRIDOM1 (NCT02301910)
- Testing
- Recombinant staphylokinase, Tenecteplase
- Where
- 17 sites in Russia
- Volunteers
- 382 people
- Sponsor
- Supergene, LLC
Urinary Incontinence
An Evaluation of the PureWick™ Male External Catheter Versus an Established Comparator Overnight in the Home Setting for Incontinence in Adult Males
This post-market study will assess the performance of and user satisfaction with the PureWick™ Male External Catheter in a home setting.
- Trial name
- PUREST-M (NCT07282860)
- Testing
- PureWick System, UltraFlex Self-Adhering Male External Catheter
- Where
- 15 sites in United States
- Volunteers
- 120 people
- Sponsor
- C. R. Bard
Chronic Kidney Disease
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease
This study is open to adults with chronic kidney disease (CKD) that is at risk of getting worse. People who have taken a specific type of medication for kidney disease called SGLT2 inhibitor within 1 month before the study or…
- Trial name
- NCT06926660
- Testing
- Vicadrostat, Empagliflozin
- Where
- 157 sites in United States, Argentina and 22 more
- Volunteers
- 492 people
- Sponsor
- Boehringer Ingelheim
Hepatitis C, Chronic, Hepatitis C
Monotherapy Versus Placebo Over 14 or 17 Days in Healthy and Hepatitis C Infected Adults
This study represents the first administration of GSK625433 in humans. The study is designed to evaluate initial safety and tolerability in healthy adults as well as anti-viral activity in Hepatitis C(HVC) infected adults.
- Trial name
- NCT00439959
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
CLL
Chronic Lymphocytic Leukemia Electronic Patient Reported Outcomes Study
This multi-site study will enroll approximately 100 CLL patients across 5 cancer institutions. The aim of the project is to ensure hematology care teams that are participating in new value-based reimbursement models have an…
- Trial name
- NCT03231579
- Testing
- Carevive CPS
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- Carevive Systems, Inc.
Osteoarthritis, Osteoarthritis, Knee
A Safety and Tolerability Study of JNJ-42160443 in Patients With Moderate to Severe, Chronic Knee Pain From Osteoarthritis
The purpose of this study is to evaluate pain relief, safety, and tolerability of a new treatment (JNJ-42160443) for moderate to severe pain of osteoarthritis of the knee in comparison to a standard pain treatment and placebo.
- Conditions
- Osteoarthritis, Osteoarthritis, Knee, Pain, Arthralgia
- Trial name
- NCT01094262
- Testing
- Oxycodone CR (standard pain medication), JNJ-42160443
- Where
- 44 sites in United States, Canada
- Volunteers
- 196 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Gastrointestinal Neoplasms, Adenocarcinoma
A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer
The Phase 1b study is an open-label, multicenter dose escalation study designed to assess the safety, tolerability, immunogenicity and recommended phase 2 dose (RP2D) of IMU-131.
- Trial name
- NCT02795988
- Testing
- IMU-131, Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and capecitabine.
- Where
- 22 sites in Georgia, India and 5 more
- Volunteers
- 64 people
- Sponsor
- Imugene Limited
EGFR Overexpression, Locally Advanced Solid Tumor
Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors
This is a study for people with locally advanced or metastatic cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with Epidermal Growth Factor Receptor (EGFR) overexpressing can…
- Conditions
- EGFR Overexpression, Locally Advanced Solid Tumor, Metastatic Solid Tumor
- Trial name
- NCT06975410
- Testing
- YH32364
- Where
- 4 sites in South Korea
- Volunteers
- 80 people
- Sponsor
- Yuhan Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.